APLS Q4 2025 Earnings — Apellis Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

APLSApellis Pharmaceuticals, Inc.

$3B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$200M-5.9% YoY

Gross Profit

$170M85.1% margin

Operating Income

-$51M-25.6% margin

Net Income

-$59M-29.5% margin

EPS (Diluted)

$-0.47

QoQ Revenue Growth

-56.4%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

-$83M

Balance Sheet

Total Assets

$1.1B

Total Liabilities

$705M

Stockholders' Equity

$370M

Cash & Equivalents

$468M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$200M	$213M	-5.9%
Gross Profit	$170M	$172M	-0.9%
Operating Income	-$51M	-$26M	-95.5%
Net Income	-$59M	-$36M	-62.2%

Revenue Segments

Product

$190M95%

Licensing And Other Revenue

$10M5%